News
1 Reason to Buy Eli Lilly (LLY) Stock
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...
CEO David Ricks and other top executives have bought nearly $2.9B worth of company stock over the past few days as the ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Click here to read an analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback